Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
Date:8/5/2011

 We have completed Phase 2b clinical studies of lesinurad and continue to advance the drug in longer term extensions in preparation for Phase 3 development.  Our next-generation URAT1 inhibitor, RDEA3170, is currently in preclinical development. BAY 86-9766 (RDEA119) is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare. BAY 86-9766 (RDEA119) is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib and a Phase 1/Phase 2 study in patients with advanced pancreatic cancer in combination with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of lesinurad (RDEA594), BAY 86-9766 (RDEA119) and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the head
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Ardea Biosciences to Present at Upcoming Investor Conferences
2. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
3. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
4. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
5. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
6. Ardea Biosciences Prices Public Offering of Common Stock
7. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
8. Ardea Biosciences to Present at Two Upcoming Investor Conferences
9. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
10. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
11. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... DIEGO , June 30, 2015  The ... Education in Biosciences (CCE/Bio) and UC San Diego ... fermentation, to be held Aug.  12 – 14, ... ).  This three-day workshop provides an intense exposure ... industrial biotechnology, and is well-suited to biologists, process ...
(Date:6/30/2015)...  The Dr. Samadi Prostate Cancer Center in ... suite of new genetic testing methods for men with an ... cancer. Dr. Samadi,s Prostate Cancer Center ... the risk and optimizing the diagnosis of prostate cancer, both ... now offer these revolutionary genetic tests to men with an ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... media company, launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by ... the most dynamic collection of legal medical cannabis stories ever assembled. , ...
(Date:6/29/2015)... KY and Manhattan, KS (PRWEB) , ... June ... ... has acquired US PATENT 7736892 B2. Under the terms of the agreement, MediVet ... Umbilical Cord Matrix Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development as ...
Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3
... of the fruit fly and roundworm,s functional genomic elements: DNA ... which genes are turned on and off at various times ... of the Human Genome Project, the genomes of the fruit ... elegans , are powerful models for understanding human biology ...
... (Nasdaq: NEOG ) announces the following Webcast:What: ... January 4, 2011 @ 11:00 ETWhere: , http://www.videonewswire.com/event.asp?id=75037 ... on to the web at the address above.  Contact: ... are unable to participate during the live webcast, the ...
... (December 21, 2010) -- A researcher known widely ... and use of minimally toxic, environmentally friendly chemicals ... Dr. Paul Anastas, science advisor to the ... for the EPA,s Office of Research and Development ...
Cached Biology Technology:Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 2Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 3Scientists reveal how biological activity is regulated in fruit fly and roundworm genomes 4Science advisor to the US EPA to speak to industry, academic leaders on sustainability innovations 2Science advisor to the US EPA to speak to industry, academic leaders on sustainability innovations 3
(Date:6/24/2015)... MARTIGNY, Switzerland , June 24, 2015 /PRNewswire/ ... strategic partnership with emerging biometric password solution one ... http://photos.prnewswire.com/prnh/20150623/225014LOGO one face in, ... offers a ground-breaking and affordable multifactor-authentication biometric answer ... speaker recognition technology, provided in partnership with KeyLemon, ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
(Date:6/23/2015)... BEACH GARDENS, Fla. , June 23, ... multi-factor identity management and authentication solutions, today announced ... Altus strong, multi-factor authentication solution.  The enhancements ... of use of the DigitalPersona Altus platform ... biometric reader compatibility. In today,s ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... Hospital scientists has identified a possible new approach to ... component in a bid to invigorate the immune response. ... function of one of the innate immune molecules is ... response to infections and other threats. Investigators showed the ...
... Albert Einstein College of Medicine of Yeshiva University ... development of myelodysplastic syndromes (MDS), serious blood diseases that are ... leukemia. The findings could lead to targeted therapies against MDS ... the online edition of the journal Blood . ...
... The next "next-gen" technology in genome sequencing has gotten a ... Cold Spring Harbor Laboratory (CSHL) and collaborators today published results ... which was recently introduced but whose use has so far ... by CSHL Assistant Professor Michael Schatz and Adam Phillippy and ...
Cached Biology News:Innate immune system protein provides a new target in war against bacterial infections 2Innate immune system protein provides a new target in war against bacterial infections 3Myelodysplastic syndromes (MDS) linked to abnormal stem cells 2An error-eliminating fix overcomes big problem in '3rd-gen' genome sequencing 2An error-eliminating fix overcomes big problem in '3rd-gen' genome sequencing 3
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to pCrosstide (HRP) ( Abpromise for all tested applications)....
IkappaB-alpha (112B2) Mouse mAb...
Human sIL-2R/CD25 ELI-PAIR Kit...
Biology Products: